MONDAY, SEPTEMBER 26, 2016

Cubist Pharmaceuticals signs agreements to acquire Trius, Optimer

Cubist Pharmaceuticals, Inc., a Lexington, Massachusetts-based biopharmaceutical company, announced the acquisition on Tuesday of Trius Therapeutics and Optimer Pharmaceuticals, both of which bring promising drug candidates to Cubist.

Trius Therapeutics, Inc., a biopharmaceutical company, brings to Cubist a late-stage antibiotic candidate, tedizolid phosphate. The investigational drug is being developed for the treatment of serious Gram-positive infections, such as infections caused by methicillin-resistant Staphylococcus aureus. Tedizolid phosphate met all primary and secondary endpoints in two Phase III clinical trials.

"Tedizolid is an exciting late-stage antibiotic candidate that we believe has the potential to be an important new tool in the infectious disease community's battle against resistant infections caused by MRSA," Michael Bonney, the CEO of Cubist, said. "We have a high regard for the entire Trius team and the excellent work they have done with the tedizolid program and their promising discovery programs. We believe our extensive clinical, regulatory, and commercial experience in acute care will allow us to complement this team's work and maximize the potential for tedizolid while driving substantial near and long-term benefits for hospitals, patients and shareholders alike."

Optimer Pharmaceuticals, Inc., a biopharmaceutical company, is focused on commercializing tablets of DIFICID, also known as fidaxomicin, a macrolide antibacterial drug used to treat Clostridium difficile-associated diarrhea or disease. DIFICID was approved by the U.S. Food and Drug Administration on May 27, 2011, in adults 18 years of age and older.

"Optimer is a natural fit for Cubist given our co-promotion of DIFICID and focus on the acute care and hospital environments," Bonney said. "There is a significant and rising need for DIFICID as CDAD infections continue to be a growing clinical and economic burden globally. Given Cubist's outstanding hospital-based commercial infrastructure and our first-hand experience co-promoting DIFICID in the U.S., we are uniquely positioned to maximize DIFICID's full potential for the benefits of patients, hospitals and our shareholders. We expect a very smooth transition, and we look forward to its contributions to creating shareholder value for many years to come."

Cubist is focused on the research, development and commercialization of pharmaceutical products that address significant unmet medical needs in an acute care environment.